^
Association details:
| Biomarker: | CLDN18.2 expression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | AZD5863 (CD3 agonist, CLDN18.2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1169 AZD5863: a specific, potent, affinity-optimized claudin 18.2 and CD3 binding T cell-engager that elicits low cytokine release and is capable of bystander killing
Published date:
11/04/2023
Excerpt:
In humanized mouse models, AZD5863 significantly inhibited the growth of CLDN18.2-expressing gastric, pancreatic and esophageal tumors compared with isotype controls.
DOI:
http://dx.doi.org/10.1136/jitc-2023-SITC2023.1169
